Tomio Nakayama

Dr. Tomio Nakayama

Division of Screening Assessment and Management, Center for Public Health Sciences, National Cancer Center
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
CHChisato Hamashima
Chisato Hamashima
OGon behalf of the Japanese Research Group for the Development of Breast Cancer Screening Guidelines
on behalf of the Japanese Research Group for the Development of Breast Cancer Screening Guidelines
CCChisato Hamashima C
Chisato Hamashima C
MHMasakazu Hattori
Masakazu Hattori
SHSatoshi Honjo
Satoshi Honjo
ASAkihiko Suto
Akihiko Suto
The incidence of breast cancer has progressively increased, making it the leading cause of cancer deaths in Japan. Breast cancer accounts for 20.4% of all new cancers with a reported age-standardized rate of 63.6 per 100 000 women. The Japanese guidelines for breast cancer screening were developed based on a previously established method. The efficacies of mammography with and without clinical breast examination, clinical breast examination and ultrasonography with and without mammography were evaluated. Based on the balance of the benefits and harms, recommendations for population-based and opportunistic screenings were formulated. Five randomized controlled trials of mammographic screening without clinical breast examination were identified for mortality reduction from breast cancer. The overall relative risk for women aged 40–74 years was 0.75 (95% CI: 0.67–0.83). Three randomized controlled trials of mammographic screening with clinical breast examination served as eligible evidence for mortality reduction from breast cancer. The overall relative risk for women aged 40–64 years was 0.87 (95% confidence interval: 0.77–0.98). The major harms of mammographic screening were radiation exposure, false-positive cases and overdiagnosis. Although two case–control studies evaluating mortality reduction from breast cancer were found for clinical breast examination, there was no study assessing the effectiveness of ultrasonography for breast cancer screening. Mammographic screening without clinical breast examination for women aged 40–74 years and with clinical breast examination for women aged 40–64 years is recommended for population-based and opportunistic screenings. Clinical breast examination and ultrasonography are not recommended for population-based screening because of insufficient evidence regarding their effectiveness.

2 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
AYAsami Yagi
Asami Yagi
Yutaka UedaYutaka Ueda
Yutaka Ueda
SNSatoshi Nakagawa
Satoshi Nakagawa
SISayaka Ikeda
Sayaka Ikeda
MKMamoru Kakuda
Mamoru Kakuda
TKTadashi Kimura
Tadashi Kimura
In 2013, the Ministry of Health, Labor, and Welfare (MHLW) in Japan announced a suspension of the governmental recommendation for routine HPV vaccinations. In 2020, MHLW started individual notifications of HPV vaccine to the targeted girls. In April 2022, the governmental recommendation was restarted, and catch-up vaccinations started. We evaluated the benefits and limitations of the MHLW’s new vaccination strategies by estimating the lifetime risk for cervical cancer for each birth FY under different scenarios to suggest a measure for the vaccine suspension generation. It was revealed that catch-up immunization coverage among the unvaccinated must reach as high as 90% in FY2022, when the program begins, in order to reduce the risk of the females already over the targeted ages to the same level or lower than that of women born in FY1994-1999 who had high HPV vaccination rates. For women whose vaccination coverage waned because of their birth FYs, strong recommendations for cervical cancer screening should be implemented.

30 December 2023 in Cancer Science
Verified
Journal Article
Open access
AYAsami Yagi
Asami Yagi
SNSatoshi Nakagawa
Satoshi Nakagawa
Yutaka UedaYutaka Ueda
Yutaka Ueda
EOEmiko Oka
Emiko Oka
SISayaka Ikeda
Sayaka Ikeda
TKTadashi Kimura
Tadashi Kimura
In 2013, the national human papillomavirus (HPV) immunization program began. However, in June 2013, Japan's Ministry of Health, Labor and Welfare (MHLW) announced a “temporary” suspension of its recommendation for the human papillomavirus vaccine. Finally, in November 2021, the MHLW ended its suspension of the recommendation of the HPV vaccine. To address the 9‐year gap in HPV vaccinations the suspension had caused, the MHLW conducted a program of catch‐up vaccinations from April 2022 to March 2025. Finally, in April 2023, the 9‐valent HPV vaccine was approved for both the routine and catch‐up vaccination programs in Japan. In this study, we investigated the potential effects of the introduction of the 9‐valent vaccine on the increased risk of cervical cancer in females born after fiscal year (FY) 2000. We estimated the lifetime relative risk of cervical cancer incidence and death using the improved routine and catch‐up vaccination rates after the recent resumption of the governmental recommendation for women and girls to have the HPV vaccination. These relative risks were calculated using a lifetime risk of 1.000 for cervical cancer incidence and death for females born in FY 1993. We predicted that even if a 90% vaccination rate were to be achieved by FY 2024 with the 9‐valent vaccine among women born between FY 2000 and FY 2005, the risk would remain higher than for the vaccination generation. Therefore, for women born between FY 2000 and FY 2005, it will be necessary to significantly improve the cervical cancer screening rate to compensate for this increased risk.

3 September 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
AYAsami Yagi
Asami Yagi
Yutaka UedaYutaka Ueda
Yutaka Ueda
TMTatsuo Masuda
Tatsuo Masuda
SISayaka Ikeda
Sayaka Ikeda
TMTakashi Miyatake
Takashi Miyatake
TKTadashi Kimura
Tadashi Kimura
The trend for cervical cancer in younger women has been increasing recently in Japan. However, as a result of the suspension of governmental recommendation, Japan’s HPV (human papillomavirus) vaccination rate for girls born since 2000 has dropped sharply. We conducted an internet survey in December of 2019, 76 months after the suspension of recommendation, to verify the intention of mothers to inoculate their daughter under current circumstances and compared with our previous surveys and leaflet intervention effect. The rates of mothers who replied that they would “inoculate” were significantly higher at 9 and 23 months, but by 32 months after the suspension the rate was significantly lower (p < 0.05, p < 0.05, p < 0.05, respectively). The rates of the mothers who replied they would not inoculate were significantly lower at 9 months and 23 months, but at 76 months was significantly higher (p < 0.05, p < 0.05, p < 0.05, respectively). We found that intervention with a leaflet that could be used under the current suspension of the governmental recommendation did not increase the mothers’ intention to inoculate their daughters. A leaflet that actively encourages vaccination may increase the intent of vaccination. It is strongly recommended that the MHLW promptly resume its recommendations for HPV vaccination.

19 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MTMariko Taniguchi
Mariko Taniguchi
Yutaka UedaYutaka Ueda
Yutaka Ueda
AYAsami Yagi
Asami Yagi
AMAi Miyoshi
Ai Miyoshi
YTYusuke Tanaka
Yusuke Tanaka
TKTadashi Kimura
Tadashi Kimura
Women born between 1994 and 1999 achieved high vaccination rates for human papillomavirus (HPV); they are now reaching the age of cervical cancer screening programs in Japan. In this study, we aimed to investigate the health awareness of HPV-vaccinated and unvaccinated women and to create tailored leaflets recommending cervical cancer screening for each. Surveys on the cancer screening rates for HPV-vaccinated and unvaccinated women aged 20 and 21 have demonstrated that the rate was significantly higher (p < 0.01) in vaccinated (6.2%) than in unvaccinated women (3.1%). Next, interviews and Internet questionnaires clarified that there was a trend that vaccinated women have a better health consciousness than the unvaccinated ones, and that in unvaccinated women, their willingness to receive cervical cancer screening was significantly enhanced by the fear of developing cancer. Finally, in a prospective study, the increase in the screening rate for both vaccinated and unvaccinated groups after they read tailored leaflets, from 6.4% to 7.4% and from 3.9% to 5.1%, respectively, was not statistically significant compared to the groups provided with a standard reminder letter. Cervical cancer control measures might be enhanced by recommending cervical cancer screening in ways better tailored to HPV vaccination status.

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
KKKanako Kono
Kanako Kono
TMTohru Morisada
Tohru Morisada
KSKumiko Saika
Kumiko Saika
EAEiko Saitoh Aoki
Eiko Saitoh Aoki
Etsuko MiyagiEtsuko Miyagi
Etsuko Miyagi
DADaisuke Aoki
Daisuke Aoki
Kono K, et al. J Gynecol Oncol. 2021 Jan;32(3):e29. https://doi.org/10.3802/jgo.2021.32.e29